Can a leukotriene inhaler be used for a patient on nightly fluticasone (Flovent) with a persistent dry cough, and what oral leukotriene blockers are appropriate?

What is a Leukotriene Inhaler?

There is no such thing as a "leukotriene inhaler"—leukotriene receptor antagonists (LTRAs) are oral medications, not inhaled drugs. The commonly available LTRAs are montelukast (Singulair), zafirlukast, and pranlukast, all taken by mouth 1, 2.

Understanding Leukotriene Modifiers

Leukotriene modifiers work by interfering with the leukotriene pathway—inflammatory mediators released from mast cells, eosinophils, and basophils 1. These are oral tablets, not inhalation devices. They include:

• Leukotriene receptor antagonists (LTRAs): Montelukast and zafirlukast
• 5-lipoxygenase inhibitors: Zileuton (requires liver function monitoring) 1

Clinical Application for Your Patient on Flovent with Persistent Dry Cough

For a patient on nightly fluticasone (Flovent) with persistent dry cough, first increase the inhaled corticosteroid dose before adding an oral leukotriene blocker 2. Here's the algorithmic approach:

Step 1: Reconsider Alternative Causes

Before escalating asthma therapy, rule out:

• Gastroesophageal reflux disease (GERD)
• Post-nasal drip/upper airway cough syndrome
• Non-asthmatic eosinophilic bronchitis (NAEB)
• Medication-induced cough (ACE inhibitors)

Step 2: Optimize Inhaled Corticosteroid Therapy

Increase the fluticasone dose first 2. The current guideline recommends stepping up ICS before adding adjunctive therapy for incomplete symptom control.

Step 3: Add Oral Leukotriene Blocker if Needed

If cough persists after ICS dose escalation, add montelukast 10 mg once daily at bedtime 2. This is the most commonly prescribed LTRA and requires no laboratory monitoring 1.

Alternative options include:

• Zafirlukast: Requires twice-daily dosing
• Zileuton: Requires liver function monitoring, making it less practical 1

Important Clinical Context

Why LTRAs Are Second-Line

Inhaled corticosteroids are superior to leukotriene blockers as monotherapy 1, 3. The evidence consistently shows:

• ICS improve asthma control more effectively than LTRAs alone
• ICS reduce exacerbations requiring oral steroids by 50% compared to LTRAs 3
• LTRAs are alternative, not preferred, therapy for mild persistent asthma 1

When LTRAs Add Value

LTRAs work best as adjunctive therapy in specific situations 2, 4:

• Incomplete response to ICS alone
• Exercise-induced bronchospasm
• Aspirin-sensitive asthma
• Concomitant allergic rhinitis

Adding an LTRA to ICS reduces exacerbations requiring oral steroids by 50% (RR 0.50,95% CI 0.29-0.86) compared to ICS alone 4. This translates to one additional patient avoiding an exacerbation for every 22 patients treated.

Critical Caveat About Cough-Variant Asthma

For cough-variant asthma (CVA) or non-asthmatic eosinophilic bronchitis (NAEB), inhaled corticosteroids remain first-line treatment 2. Fluticasone has demonstrated efficacy specifically for cough reduction in otherwise healthy adults 5, though this effect is diminished in smokers.

Safety Considerations

• No increased risk of adverse events with LTRA addition to ICS 4
• Exception: When tapering ICS doses, serious adverse events increased with LTRA use (RR 2.44) 4
• Montelukast does not require laboratory monitoring, unlike zileuton 1

Bottom Line for Your Patient

Start by increasing the Flovent dose. If cough persists after 4-6 weeks, add montelukast 10 mg nightly 2. Do not substitute an LTRA for the ICS—they work synergistically, not interchangeably.